Clinical effects of K-18 (IgG-melphalan) in hypoplastic leukemia: a case report
Takahashi, I.; Ohmoto, E.; Nakada, H.; Inagaki, N.; Nonaka, K.; Takeuchi, M.; Osada, K.; Tsurumi, N.; Uchida, K.; Yorimitsu, S.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(1): 159-162
1988
ISSN/ISBN: 0385-0684 PMID: 2447835 Document Number: 308785
Five cases of hypoplastic acute myelocytic leukemia were treated with an IgG-melphalan conjugate, K-18. Eight tablets of K-18, containing 30 mg per tablet, were given daily. One patient, a 68-year-old female, obtained complete remission with a duration of 1.5 + months. Among the four remaining patients without remission, one showed a decrease in leukemic cells in the peripheral blood. No side effects of K-18 were observed except in one patient, showing a slight increase in serum GOT and GPT levels. Further studies with a large group will be necessary to clarify the effect of this drug on hypoplastic leukemia.